SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: Woman stepping onto scale/Courtesy Getty
Drug Development
Viking Enters Weight-Loss Arena with Promising Phase I Data
Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.
March 29, 2023
 · 
2 min read
 · 
Tristan Manalac
courtesy of Shutterstock
Drug Development
Positive Phase III Builds Case for Intra-Cellular’s Depression Drug
Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.
March 29, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy Jeremy Moeller/Getty Images
Business
Evotec Up for Potential $4B More in Lucrative BMS Partnership
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
March 28, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Kena Betancur/Getty Images
Drug Development
Keytruda Maintains Edge over GSK’s Jemperli in Endometrial Cancer (Updated)
Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, based on late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting.
March 28, 2023
 · 
2 min read
 · 
Tristan Manalac
A Novartis building under a blue sky/courtesy of C
Drug Development
Novartis’ Kisqali Cuts Recurrence Risk in Early-Stage Breast Cancer
Topline data from the Phase III NATALEE study showed Novartis’ Kisqali met its primary endpoint, reducing the risk of recurrence in early breast cancer.
March 27, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Pharming’s Leniolisib Gains FDA Approval in Ultra-Rare Disease
The FDA approved Pharming’s leniolisib, now to be marketed as Joenja, for the treatment of the ultra-rare disease-activated phosphoinositide 3-kinase delta syndrome, the company announced Friday.
March 27, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Sarah Silbiger/Getty Images
Policy
FDA Action Alert: Roche, Emergent and More
The FDA is expected to make decisions on Emergent BioSolutions’ sNDA for OTC Narcan and Roche’s Polivy in frontline DLBCL.
March 24, 2023
 · 
3 min read
 · 
Tristan Manalac
The PTC Therapeutics logo is pictured on a phone s
Policy
NICE Backs PTC’s Gene Therapy for Ultra-Rare Pediatric Disease
Upstaza is the first targeted therapy for aromatic L-amino acid decarboxylase (AADC) deficiency. PTC expects to submit a Biologics License Application to the FDA in the first half of 2023.
March 24, 2023
 · 
2 min read
 · 
Tristan Manalac
SKYRIZI is the new option for psoriatic arthritis.
Drug Development
AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus
In a double data drop Thursday, AbbVie touted two clinical trial wins, for Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus.
March 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Dupixent Clears Phase III in Bid to Become First Biologic for COPD
Sanofi and Regeneron’s Dupixent (dupilumab) met its primary and all secondary endpoints in the Phase III BOREAS trial, significantly reducing severe exacerbations in COPD.
March 23, 2023
 · 
2 min read
 · 
Tristan Manalac
John Tlumacki/The Boston Globe via Getty Images
Drug Development
FDA Adcomm Backs Accelerated Approval of Biogen’s Tofersen in SOD1-ALS
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that tofersen’s effect on neurofilament light chain (NfL) could be a reasonable predictor of clinical benefit.
March 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Young team during virus lab tests. Multi ethnic scientists focused on work. Wearing protective workwear
Drug Development
Mid-Stage Win Gives 89Bio a Boost in NASH Race
Data from the Phase IIb ENLIVEN trial showed 89bio’s pegozafermin met its primary histology endpoint in NASH patients, giving the company an edge in the competitive space.
March 22, 2023
 · 
3 min read
 · 
Tristan Manalac
Pictured: Stack of coins/Courtesy Getty Images
Genetown
Pfizer-Backed Flare Seeks Transcription Factor Therapies with $123M Series B
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
March 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: BioNTech Headquarters/Courtesy of Getty
Business
With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy
BioNTech inked an exclusive worldwide license and collaboration agreement with OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors.
March 21, 2023
 · 
2 min read
 · 
Tristan Manalac
In Control Room Doctor and Radiologist Discuss Diagnosis while Watching Procedure and Monitors Showing Brain Scans Results, In the Background Patient Undergoes MRI or CT Scan Procedure.
Drug Development
Karuna’s KarXT Aces Third Registrational Study in Schizophrenia
Karuna Therapeutics released data Monday from the Phase III EMERGENT-3 trial showing that KarXT met the primary endpoint, significantly improving symptom severity.
March 20, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More